STVN
Stevanato Group S.p.A.
NYSE · ITHealthcareMedical - Instruments & Supplies
$19.15-0.10%
Price as of Jul 20, 2026
STVN growth
Stevanato Group S.p.A. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +6.7%
- EBITDA
- -1.5%
- EBIT
- +16.6%
- EPS
- +9.5%
- Free cash flow
- +95.9%
- Operating cash flow
- -6.4%
Forward estimates
- Revenue
- +31.4%
- EBITDA
- +33.0%
- EPS
- +63.0%
Three-year CAGR
- Revenue
- +5.0%
- EBITDA
- +4.0%
- EBIT
- -1.6%
- Net income
- -2.0%
- EPS
- -2.6%
- Free cash flow
- +113.6%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.